Merck & Co., Inc. Stock

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse 04:01:04 2024-04-19 pm EDT After market 05:13:59 pm
125.8 USD +0.44% Intraday chart for Merck & Co., Inc. 124.3 -1.21%
Sales 2024 * 63.88B Sales 2025 * 68.19B Capitalization 317B
Net income 2024 * 19.48B Net income 2025 * 21.78B EV / Sales 2024 * 5.27 x
Net Debt 2024 * 19.65B Net Debt 2025 * 7.53B EV / Sales 2025 * 4.76 x
P/E ratio 2024 *
16.1 x
P/E ratio 2025 *
14.1 x
Employees 71,000
Yield 2024 *
2.45%
Yield 2025 *
2.58%
Free-Float 70.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.40%
1 week+0.03%
Current month-4.68%
1 month+2.93%
3 months+5.80%
6 months+25.24%
Current year+15.37%
More quotes
1 week
124.50
Extreme 124.5
127.82
1 month
120.38
Extreme 120.38
133.10
Current year
109.16
Extreme 109.16
133.10
1 year
99.14
Extreme 99.14
133.10
3 years
70.89
Extreme 70.89
133.10
5 years
65.25
Extreme 65.25
133.10
10 years
45.69
Extreme 45.69
133.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 14-03-31
Director of Finance/CFO 55 89-12-31
Chief Tech/Sci/R&D Officer 55 20-07-31
Members of the board TitleAgeSince
Director/Board Member 63 07-11-26
Director/Board Member 67 15-08-31
Director/Board Member 69 18-02-28
More insiders
Date Price Change Volume
24-04-19 125.8 +0.44% 8 403 025
24-04-18 125.2 -0.11% 5,992,700
24-04-17 125.4 +0.25% 6,122,908
24-04-16 125.1 -0.90% 5,587,332
24-04-15 126.2 +0.36% 6,241,069

Delayed Quote Nyse, April 19, 2024 at 04:01 pm EDT

More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
125.2 USD
Average target price
137.7 USD
Spread / Average Target
+9.92%
Consensus